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Objective. To determine the inﬂuence of comorbidity on survival in early-stage lung cancer patients treated with proton
radiotherapy, using the Charlson Comorbidity Index. Study Design and Setting. Fifty-four non-small-cell lung cancer patients,
treated prospectively in a phase II clinical trial with hypofractionated proton therapy, were analyzed retrospectively to assess their
burden of comorbid disease as expressed by Charlson Comorbidity Index. Using the Charlson Comorbidity Index method, a
predicted survival curve based on comorbidity was formulated and compared to the observed mortality from causes other than
lung cancer in the study population. Results. The study population had an average age score of 2.8 and an average Charlson
Comorbidity Index of 4.7.Predicted survival was calculated to be 67% and 50% at 2 and 4 years, respectively. Actual comorbidity-
speciﬁc survival at 2 and 4 years was 64% and 45%, respectively. The observed survival fell within the 95% conﬁdence intervals of
the predicted survival at all time points up to 5 years. Conclusion. Predicted mortality from concurrent disease, based on Charlson
Comorbidity Index, correlated well with observed comorbidity-speciﬁc mortality. This helps substantiate the accuracy of the data
coding in cause of death and strengthens previously reported disease-speciﬁc survival rates.
1.Introduction
More people die from lung cancer than from any other type
of cancer. It continues to be the leading cause of cancer
death in both men and women, with an estimated 161, 840
deaths in 2008 [1]. The patient population aﬀected by lung
cancer is generally older: the average age is 71 years at the
time of diagnosis [1]. A higher prevalence of comorbidity
is associated with age; thus, lung cancer patients tend to
have more comorbidities. Additionally, given the causative
association of tobacco smoking, chronic pulmonary and
cardiovascular diseases are commonly seen in this patient
population.
In oncological studies, eﬃcacy of treatment is often
evaluated in terms of survival outcome. This can be prob-
lematic in lung cancer, as the high incidence of concomitant
illnesses exerts a confounding inﬂuence on assessing survival
outcome. Many studies exploring nonsurgical treatment in
early stage lung cancer report promising disease-speciﬁc
survival (DSS), but overall survival (OS) remains poor.
Fakiris et al. reported a 3-year DSS of 81.7% in early stage
non-small-cell lung cancer (NSCLC) patients treated with
stereotactic body radiation (SBRT), but an OS of 42.7% [2].
Salazar explored once-weekly, high-dose SBRT in inoperable
patients, which included 60 stage I patients; the 5-year
DSS and OS rates were 70% and 47%, respectively [3]. A
study conducted in Japan by Uematsu et al., also exploring
SBRT, reported 3-year DSS and OS rates of 88% and 66%,
respectively, [4]. The disparity between DSS and OS can
be explained by advanced age and high mortality from
comorbid illnesses in this patient population.
It is clear that disease-speciﬁc survival is a more appro-
priate endpoint than overall survival in examining therapeu-
tic outcome in lung cancer patients. However, determining
DSS is not entirely exempt from subjectivity. The patho-
physiology of multiple comorbidities in lung cancer patients
are integrated, and death attributable to a single speciﬁc
cause can be diﬃcult to ascertain. Determining the cause of
death requires a judgment call that cannot always be made
objectively. This paper employs the Charlson Comorbidity
Index (CCI) to elucidate the inﬂuence of comorbidity. Using
the Charlson model, a predicted survival curve can be2 Journal of Oncology
100
90
70
50
30
10
(a)
0
20
40
60
80
100
V
o
l
u
m
e
(
%
)
10 20 30 40 50 60 70
Dose (Gy)
(b)
Figure 1: (a) Representative treatment plan. Colored contour lines
indicate percentage of total dose given. (b) Dose-volume histogram
showing doses given to volumes of tumor (red) and lung (green).
formulated based on patients’ baseline medical problems
[5]. In other words, the life expectancy of a speciﬁc cohort
of patients, based on their comorbidities, can be estimated.
This study uses the CCI tool and predicted survival as an
alternativestatisticalanalysis tovalidatepreviouslypublished
results of hypofractionated proton beam radiotherapy for
stage I NSCLC [6].
2.Methods
Patients evaluated for this report were treated at Loma
Linda University Medical Center under an IRB-approved
phase II protocol utilizing proton beam radiotherapy [6].
Informed consent was obtained from all subjects, who
had a histologic diagnosis of NSCLC and clinical stage I
disease; all were medically inoperable or refused surgical
resection. Each patient received a two-week course of proton
radiation, delivered in 10 fractions, of either 51 or 60 CGE
to the target volume. The proton dose was calculated to
a point in the center of the tumor and the 95% isodose
line completely covered the target volume. The mediastinum
was not treated. A representative treatment plan, including
isodose distribution, is shown in Figure 1.
Charts for 54 of these patients were reviewed, and
each patient was assigned a CCI score based on age and
pre-existing illnesses. Comorbibities for each patient were
obtained from the initial consultation and clinical data
obtained throughout followup. The average score was deter-
mined for the entire cohort, and a representative predictive
survival curve for the cohort was generated using the same
model as in the validation phase of the original Charlson
paper [5]. Relative risk was calculated from the proportional
hazards model used to create a single prognostic variable
combining age and comorbidity; a value indicative of
subsequent risk was obtained using the equation
e0.9(comorbidity + age score) = RR. (1)
Predicted survival was calculated based on a theoretical low-
risk population, using the equation
SRR
o = predicted survival, (2)
where So isthe survival ofthetheoreticallow-risk population
at a given time point and RR is the relative risk.
The predicted survival curve based on the patient’s
Charlson score was then compared to the observed
comorbidity-speciﬁc survival (CSS). Since the objective is to
compare the observed mortality due to comorbidity with the
CCI-based predicted mortality, patients who died from their
lung cancers were treated as withdrawn alive, or censored, at
thetimeofdeath.CSSwascalculatedusingtheKaplan-Meier
method, which is reﬂective of the diﬀerence between overall
survival and disease-speciﬁc survival.
3.Results
Chronic pulmonary disease was the most prevalent comor-
bidity, aﬀecting 74% of the patients evaluated; 50% of the
patients had multiple comorbid illnesses. Only the illnesses
that were found to be prognostic for mortality and part of
the Charlson weighted index were included. The weighted
index of comorbidity and the number of patients in our
cohort withthe conditionare listed inTable 1. The CCIscore
incorporates the patient age score, which is computed by
assigning a point for each decade over age 40. The average
age of the patients was 72 years, the average age score was 2.8
years, the average CI score was 1.9, and the average CCI was
4.7.
Predicted survival and observed comorbidity-speciﬁc
survival correlated well. At 3 years the predicted survival
we would expect based on the Charlson comorbidity index
is 62%, and the observed 3-year CSS is 57% (Figure 2).
At all time points, the two survival curves correlated well.
The predicted curve lies within the 95% conﬁdence interval,
indicating no statistically signiﬁcant diﬀerence between
observed CSS and the predicted curve.
4.Discussion
The Charlson index is a weighted value that takes into
account the number and severity of comorbid diseases and
allows calculation of a risk score for individual patients
that is prognostic for mortality. The CCI has been validated
in numerous oncology studies and is widely used as aJournal of Oncology 3
Table 1: Weighted index of comorbidity.
Assigned weights
for diseases Conditions No. of patients
with condition
1
Myocardial infarct 6
Congestive heart failure 8
Peripheral vascular disease 6
Cerebrovascular disease 7
Dementia 0
Chronic pulmonary disease 40
Connective tissue disease 3
Ulcer disease 2
Mild liver disease 0
Diabetes 9
2
Hemiplegia 0
Moderate or severe renal
disease 1
Diabetes with end organ
damage 0
Any tumor 8
Leukemia 1
Lymphoma 0
3 Moderate or severe liver disease 0
6 Metastatic solid tumor 0
AIDS 0
0
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Figure 2: Survival curves showing actual comorbidity-speciﬁc
survival and predicted survival, with 95% conﬁdence intervals.
prognostic tool. Birim et al. examined NSCLC patients
treated with resection to validate the inﬂuence of CCI
on outcome and found that CCI is strongly correlated
with higher risk of surgery and is a better predictor than
individual risk factors [7]. Hall et al., in investigating the
impact of age and comorbidity on survival outcomes and
treatment patterns in prostate cancer, advocated the use of
CCI in research outcomes and treatment decision-making
[8]. Finding that CCI has been widely used and validated
throughout the oncology literature, the same authors devel-
oped an electronic application for rapidly calculating CCI
score, making the tool easier to use in clinical research [9].
Using the Charlson model, a predicted survival curve can be
formulated to estimate the expected baseline mortality due
toapatient’scomorbidity.Thismethodprovidesanobjective
means to assess life expectancy based on patients’ concurrent
medical illness asidefromthe indexdisease ofinterest, inthis
case, lung cancer.
Due to the high prevalence of comorbidity associated
with age and tobacco use in lung cancer patients, optimizing
deﬁnitive radiotherapy as alternative treatment for medically
inoperable patients with early stage disease is an important
area of investigation. Historically the experience with con-
ventionalradiotherapyforearlystageNSCLChasbeendisap-
pointing, with a poor 3-year overall survival rate of approx-
imately 32% and disease-speciﬁc survival of approximately
43% [10, 11]. However, in patients treated with hypofrac-
tionatedprotonbeamtherapy,theresultsaremore favorable.
A disease-speciﬁc survival rate of 72% at 3 years has been
recorded. The dose distribution properties of proton therapy
confer considerable advantages in focal targeting of tumor
while minimizing dose to the surrounding normal tissues;
studies have demonstrated reduced doses to normal tissues
in lung cancerpatients when compared to X-ray-based treat-
ments [12].The improved outcomesare likelyattributableto
superior tissue targeting and the enhanced biological eﬀect
of hypofractionation. Inasmuch as the results of the present
study show that the predicted mortality from concurrent
disease based on the CCI correlated well with the observed
comorbidity-speciﬁc mortality, this helps substantiate the
accuracy of the data coding in cause of death and, in turn,
strengthens the validity of the reported disease-speciﬁc sur-
vival rate obtained with hypofractionated proton radiation.
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